loading
Precedente Chiudi:
$102.97
Aprire:
$102.97
Volume 24 ore:
399.41K
Relative Volume:
0.58
Capitalizzazione di mercato:
$5.41B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-15.91
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
+0.20%
1M Prestazione:
-3.48%
6M Prestazione:
+19.00%
1 anno Prestazione:
+31.65%
Intervallo 1D:
Value
$102.26
$104.83
Intervallo di 1 settimana:
Value
$102.00
$106.60
Portata 52W:
Value
$72.21
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
Nome
Axsome Therapeutics Inc
Name
Telefono
(212) 332-3241
Name
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
Dipendente
589
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
AXSM's Discussions on Twitter

Confronta AXSM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AXSM
Axsome Therapeutics Inc
103.91 5.41B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-03 Iniziato Oppenheimer Outperform
2025-04-07 Iniziato Jefferies Buy
2025-02-11 Iniziato Deutsche Bank Buy
2024-12-31 Reiterato Mizuho Outperform
2024-09-03 Iniziato Wells Fargo Overweight
2024-08-06 Aggiornamento BofA Securities Neutral → Buy
2024-07-22 Iniziato Needham Buy
2024-04-29 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-03-19 Iniziato Robert W. Baird Outperform
2024-02-06 Iniziato UBS Buy
2024-01-25 Iniziato RBC Capital Mkts Outperform
2023-12-13 Iniziato Citigroup Buy
2023-08-08 Aggiornamento BofA Securities Underperform → Neutral
2023-01-05 Iniziato Piper Sandler Neutral
2022-11-01 Iniziato Loop Capital Buy
2022-09-07 Ripresa Mizuho Buy
2021-08-10 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-06-10 Iniziato Berenberg Buy
2021-01-08 Iniziato Jefferies Buy
2020-12-16 Iniziato Mizuho Buy
2020-09-29 Iniziato BofA Securities Underperform
2020-09-10 Iniziato Morgan Stanley Overweight
2020-04-28 Reiterato H.C. Wainwright Buy
2020-04-14 Iniziato Cowen Outperform
2019-12-30 Reiterato H.C. Wainwright Buy
2019-12-17 Reiterato H.C. Wainwright Buy
2019-12-16 Reiterato Guggenheim Buy
2019-10-16 Iniziato Guggenheim Buy
2019-09-18 Iniziato William Blair Outperform
2019-05-28 Iniziato SunTrust Buy
2019-05-23 Reiterato H.C. Wainwright Buy
2019-04-08 Iniziato SVB Leerink Outperform
2019-03-15 Reiterato H.C. Wainwright Buy
2016-10-03 Ripresa Brean Capital Buy
2015-12-15 Iniziato Cantor Fitzgerald Buy
2015-12-14 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Axsome fell after FDA refuses to review AXS-14 application - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive

Jun 11, 2025
pulisher
Jun 11, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga

Jun 09, 2025

Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Axsome Therapeutics Inc Azioni (AXSM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Murdock Hunter R.
General Counsel
Jun 23 '25
Option Exercise
29.91
6,014
179,879
6,014
Murdock Hunter R.
General Counsel
Jun 20 '25
Sale
102.47
7,500
768,525
0
Murdock Hunter R.
General Counsel
Jun 23 '25
Sale
100.12
6,014
602,122
0
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):